Bolus fluorouracil and leucovorin has been accepted as the standard adjuvant therapy in stage III colon cancer for many years. New drugs such as irinotecan, oxaliplatin and oral fluoropyrimidines have all completed phase III randomised evaluation in colon cancer. Several of these studies have been reported in the last 24 months. Oxaliplatin-based chemotherapy is now emerging as the new standard of care in adjuvant treatment of stage III colon cancer. The advent of monoclonal antibodies such as cetuximab and bevacizumab has further broadened the treatment horizon for colorectal cancer and they are the focus of the on-going randomised studies in adjuvant therapy of colon cancer. In stage II colon cancer, adjuvant treatment remains controversial and is not routinely recommended in all medically fit patients by the current American Society of Clinical Oncology guidelines, except several subsets including poorly differentiated histology, T4 lesions, bowel perforation presentation and inadequately sampled lymph nodes (<13). This review focuses on the relative merits of these agents, their safety, duration of treatment, timing of commencing treatment after surgery and the role of adjuvant therapy in stage II colon cancer, thereby assisting clinicians in deciding the optimal adjuvant treatment for patients in routine clinical practice.
introduction
Colorectal cancer (CRC) represents a major public health problem accounting for over 1 million cases of new cancers and about half a million deaths worldwide [1] . Despite curative surgery in those presenting early, the risk of recurrence is significantly high. Hence much work has been done in search of effective adjuvant therapy for the eradication of micrometastases. In colon cancer, chemotherapy is the principal adjuvant therapy and the addition of radiotherapy to chemotherapy has not been shown to improve outcome [2] . Recently, newer drugs with significant impact in the treatment of metastatic CRC such as irinotecan, oxaliplatin and oral fluoropyrimidines have all completed phase III randomised testing in the adjuvant setting of colon cancer. In this review, we have focused on the implications of these trial results on the everyday management decisions of adjuvant therapy in colon cancer.
what is the efficacy of adjuvant therapy in colon cancer?
The establishment of adjuvant chemotherapy as standard treatment in stage III colon cancer was based on an improvement in overall survival (OS) compared to surgery alone. However, using OS as the primary endpoint requires many years of follow-up and may delay the introduction of effective treatment into routine clinical practice. There have been contemporary interests in using disease free survival (DFS) as a surrogate endpoint for OS for both colon cancer [3] [4] [5] [6] and other solid tumours [7] [8] [9] [10] [11] [12] . This is especially true in cancer types in which a number of treatment options exist for recurrent disease such as breast cancer [7] [8] [9] [10] [11] [12] , but not in those in which treatment options are limited such as lung cancer [13, 14] or pancreatic cancer [15] , where OS is more often used as the primary endpoint for adjuvant treatment.
Pooling individual patient data from 20 898 patients in 18 randomised controlled trials (RCTs) for colon cancer, a high correlation has been shown between 3-year DFS and 5-year OS with formal statistical surrogacy criteria being met [16] . However, all these studies used 5-FU ± leucovorin (LV) ± levamisole as adjuvant treatment. Whether these results can be extrapolated to combination adjuvant treatment with oxaliplatin or irinotecan remains to be seen. Similar to breast cancer, with the plethora of new treatment options in advanced CRC, the benefit of adjuvant treatment in improving DFS will have a diluted effect on OS. One cautionary tale would be the use of adjuvant anastrazole in breast cancer in which DFS advantage over tamoxifen did not translate into OS benefit [17] . Longer follow-up with 10-year OS rate rather than the traditional 5-year OS may be needed to truly evaluate the impact of these new agents on OS in colon cancer.
However, the definitions of DFS vary among studies and this could lead to quite different conclusions in individual studies [3, 4] . The events that generally contribute to the DFS definition include recurrence of disease, second CRC and death from any cause. Some studies also included development of second noncolorectal cancers as an event whereas others do not [18] . Inclusion of second non-colorectal cancer would capture the potential complications of treatment-induced second malignancies, a factor particularly pertinent in assessing the use of monoclonal antibodies as adjuvant treatment where very limited long-term safety data are currently available. However, whether second non-colorectal cancer is included or not as an event in DFS, the effect is likely to be small when DFS is assessed at 3 years. If the impact of the definition on the study conclusion is important, it suggests that conclusions either way may be premature or of lessened clinical importance [18] . In other cancers, DFS does include occurrence of second cancers other than the primary (ipsilateral or contralateral) site [7] [8] [9] .
Bolus 5-FU/leucovorin (LV)
Although clinical trials began in the 1960s, no definite survival advantage was seen with adjuvant therapy compared with surgery alone until the late 1980s [19] . National Surgical Adjuvant Breast and Bowel Project (NSABP) C-01, reported in 1988, was the first study to report a survival advantage for adjuvant chemotherapy [20] . Although adjuvant chemotherapy initially demonstrated both DFS and OS advantage over surgery alone [20] , this improvement was lost with prolonged follow-up at 10 years (hazard ratio [HR]: 1.12; 95% confidence interval (CI): 0.91-1.38; P = 0.27) [21] . Interestingly, bacillus CalmetteGuérin treatment in this study did not prevent tumour recurrence, but an OS benefit was seen at 10 years compared with surgery (HR: 1.27; 95% CI: 1.03-1.56; P = 0.02). This improvement in OS appeared to be due to a smaller number of deaths from co-morbidities including cardiac-related deaths, deaths after second primary non-colonic cancer and deaths from non-malignant conditions [21] .
The Intergroup 0089 compared 5-FU/levamisole with 5-FU/ low dose LV, 5-FU/ high dose LV and 5-FU/low dose LV/ levamisole in 3561 patients [22] . Whereas no significant differences in DFS or OS were seen among the four treatment arms, with prolonged follow-up (median 10 years), the trial shed some light on the natural history of patients with high risk colon cancer. In particular, between 5 and 10 years, about 10% of patients would have a further cancer-related event (an absolute decrease of 10% in DFS) and about 14% of patients died (an absolute decrease of 14% in OS). The long term results from NSABP C-01 also showed a 16% decrease in DFS and 18% decrease in OS between 5 and 10 years in patients receiving adjuvant chemotherapy [21] .
More recent European adjuvant studies aimed to confirm results from the USA. Table 1 shows selected randomised studies evaluating bolus 5-FU based adjuvant chemotherapy in colon cancer [23] [24] [25] [26] [27] [28] [29] . Collectively, the evidence emerging from these USA and European studies shows that: (i) 5-FU/low dose LV (20 mg/m 2 ) is equivalent to 5-FU/high dose LV (200-500 mg/ m 2 ); (ii) 5-FU/LV given for 6 months is as good as given for 12 months; (iii) there is no significant difference between the two most commonly used bolus 5-FU/LV dose schedules: 5-FU 425 mg/m 2 and LV 20 mg/m 2 days 1-5 every 4 weeks for six cycles (Mayo clinic regimen) and 5-FU 500 mg/m 2 and LV 500 mg/m 2 weekly ·6 every 8 weeks for three to four cycles (Roswell Park regimen); (iv) 5-FU/levamisole given for 6 months is inferior to the same treatment given for 12 months; (v) interferon produces no additional survival benefit at the expense of excessive toxicities.
Continuous infusion 5-FU
Continuous infusion of 5-FU resulted in less haematological toxicities and a small, but statistically significant survival advantage over bolus regimens in advanced CRC, thus provided the rationale to investigate continuous infusion 5-FU as adjuvant therapy. Three RCTs have been performed to compare continuous infusion 5-FU with bolus 5-FU as adjuvant therapy in colon cancer. Table 2 shows the details of these three studies [30] [31] [32] [33] . In all three studies, no statistical significant differences were seen in either DFS or OS, whereas toxicity profile was more favourable for continuous infusion 5-FU (as discussed later). It is reasonable to consider continuous infusion 5-FU instead of bolus 5-FU/LV as adjuvant therapy depending on treating clinicians' and patients' preference. These data also supported the use of LV5FU2 (a continuous infusion 5-FU/LV regimen) as control arms in phase III studies evaluating combination of oxaliplatin or irinotecan with LV5FU2. The Pan-European Trials in Adjuvant Colon Cancer (PETACC) 2 trial compared three different continuous infusion 5-FU schedules with bolus 5-FU/LV and final data are still awaited. Other continuous infusion schedules may be as effective as LV5FU2 in adjuvant therapy for colon cancer. However, continuous infusion is cumbersome to use and compromises patients' independence. Moreover, the ports and pumps required for continuous infusion with the associated complications of central intravenous catheters may result in considerable patients' inconvenience and treatment delivery costs.
Oral fluoropyrimidines
Oral fluoropyrimidines may overcome some of the shortfalls in delivering continuous infusion 5-FU, potentially translating into cost-saving measures. In advanced CRC, capecitabine has been shown to increase the response rate and has equivalent survival while achieving a more favourable toxicity profile compared to bolus 5-FU/LV [34] .
Two studies investigated the efficacy of oral fluoropyrimidines as adjuvant therapy in colon cancer. Table 3 shows the details of these two studies [35, 36] . The X-ACT study was designed to demonstrate the equivalence of capecitabine and bolus 5-FU/LV in terms of DFS and it met its primary endpoint (HR: 0.87; 95% CI: 0.75-1.00; P < 0.001 for equivalence) [35] . NSABP C-06 again did not show any difference in efficacy between UFT/LV and bolus 5-FU/LV [36] . A further pooled analysis of three randomised trials of oral fluoropyrimidines and mitomycin C versus observation alone performed in Japan has been published [37] . 5233 stage II and III patients were included in this analysis. As all three trials were initiated before 1990, observation alone after surgery for stage III patients was justified. Oral fluoropyrimidines treatment resulted in an improvement in overall survival over surgery alone (HR: 0.89; 95% CI: 0.80-0.99; P = 0.04). However, since UFT is neither licensed nor routinely used in many countries including the USA, probably only capecitabine will be integrated into the adjuvant therapy of colon cancer in routine clinical practice.
Combination chemotherapy in adjuvant treatment
Irinotecan and oxaliplatin had made a significant impact in metastatic CRC in recent years. Evaluating these two agents in the adjuvant setting was therefore logical. Considering the survival benefit of having access to all three active drugs -fluoropyrimidines, irinotecan, oxaliplatin in recurrent or metastatic CRC [40] , the use of oxaliplatin-based salvage at the time of recurrence in the LV5FU2 arm may dilute the benefit of FOLFOX in improving DFS. In contrast, all three RCTs evaluating irinotecan had failed to show a benefit of adding irinotecan to bolus or continuous infusion 5-FU/LV in improving the DFS, therefore irinotecan should not be used routinely in the adjuvant setting [4, 6, 38] . As discussed before, the definition of DFS could be critical in the conclusions of a study. PETACC-3 included second noncolorectal cancer as an event in DFS [4] , where this was not included in the MOSAIC study [3] . The relapse free survival (RFS) excluded second non-colorectal cancer and was used as a secondary endpoint in the PETACC 3 study. Therefore RFS in PETACC 3 was identical to DFS in MOSAIC study. There was indeed a statistically significant improvement in RFS in favour of FOLFIRI (irinotecan/bolus and continuous infusion 5-FU/ LV) in PETACC 3 study. The ACCORD study targeted high risk stage III colon cancer, but the expected 15% difference in 3-year DFS (from 45% with LV5FU2 to 60% with FOLFIRI) was far too optimistic [6] . Thus the study was underpowered to show any smaller but clinically meaningful differences. Secondly, similar to PETACC 3, T-staging was not a stratification factor in the randomisation process leading to a statistically significant imbalance of T4 versus T1-3 tumours in both studies, although it is debatable of whether any formal statistical testing should be performed at all on baseline characteristics in large RCTs. However, T-staging was included as a stratification factor in the MOSAIC study. CALGB C89803 study used irinotecan/bolus 5-FU/LV (IFL) regimen which had a considerable safety issue [41] and IFL was inferior in efficacy to FOLFOX in advanced CRC [42] . Therefore one may conclude that irinotecan adjuvant studies performed thus far were not adequately designed and the value of irinotecan is still to be proven. With over 3700 patients recruited into these three studies with no apparent benefit, further large scale RCTs evaluating irinotecan as adjuvant treatment will be unlikely to be performed. However, this also illustrated the importance of not extrapolating efficacy data in advanced CRC into adjuvant setting without randomised confirmatory data, especially with the advent of monoclonoal antibodies in CRC.
how safe is adjuvant chemotherapy?
Whereas continuous infusion schedules of 5-FU/LV has shown equivalent efficacy to bolus schedules, continuous infusion 5-FU had a much more favourable toxicity profile. Neutropenia, diarrhoea and stomatitis all occurred significantly less frequently. However, hand foot syndrome was observed more often with the continuous infusion schedule. Table 4 shows comparisons of grade 3/4 toxicities [30, 32, 33] . Capecitabine was also associated with similar favourable toxicity profile to continuous infusion 5-FU [35] . Interestingly, despite objective toxicity, as assessed by health care professionals, was less with capecitabine, there was no difference in global quality of life (QoL) between capecitabine and bolus 5-FU/LV [35] . This might be related to the timing of self reported QoL assessment, as this improvement in QoL was seen with continuous infusion 5-FU, when compared with bolus 5-FU/LV, if assessment was performed weekly in the first course of chemotherapy [43] . In the NSABP C-06 study, oral treatment with UFT/LV was perceived by patients as more convenient than standard intravenous bolus 5-FU/LV. While the pattern of symptoms associated with each regimen was different, the impact on QoL in general, and within the categories of colon-specific, physical, emotional, social, and functional health, was similar [44] .
Despite oxaliplatin has shown improved efficacy to LV5FU2, this improvement came at a price of added toxicity. Table 5 shows comparisons of grade 3/4 toxicities between continuous infusion 5-FU alone or in combination with oxaliplatin or irinotecan. Most notably, nausea and vomiting, neutropenia and parathesia were more commonly seen with FOLFOX, than with LV5FU2. Although neutropenia was more frequent with FOLFOX, the incidence of febrile neutropenia was 1.8% which was statistically significantly higher than LV5FU2 at 0.2% (P < 0.001) [3] , but this might not be important clinically. Nevertheless 44% of patients developed grades 2-3 peripheral neuropathy during treatment, which decreased to 5.9% one year post-treatment and 3.9% at 18 months of follow-up. Residual functional neuropathy is much less acceptable in patients who have had a potentially curative resection. Another large phase III XELOX-A study randomised patients between oxaliplatin/ capecitabine (XELOX n = 937) or bolus 5-FU/LV (n = 924) in stage III colon cancer. Efficacy data are expected in late 2007.
Early safety data of XELOX were comparable to FOLFOX except neutropenia which appears to occur at lower frequency (8%) with XELOX [45] . This has led to the acceptance of using adjuvant XELOX in some patients with contra-indications to pumps and central venous catheters.
Concerns have been raised over the safety of irinotecan when given in combination to bolus 5-FU/LV (IFL regimen). Higher than expected 60-day all cause mortality rates were noted in the CALGB C89803 study (2.2% in IFL versus 0.8% in control arms) [41] . This was attributed to a gastrointestinal syndrome characterised by diarrhoea, nausea and vomiting, dehydration coupled with febrile neutropenia and electrolyte imbalances and a vascular syndrome characterised by acute, fatal myocardial infarction, cerebrovascular accident and pulmonary embolism. Treatment related mortality with IFL was concerning and not acceptable in adjuvant settings. The nearly three-fold increase in early mortality in a relatively underpowered study may be contributory to the lack of survival benefit over bolus 5-FU/LV in the C89803 trial. However, when irinotecan was combined with continuous infusion 5-FU, mortality rate was 0.9% in the PETACC [4] and 0.5% in the ACCORD 2 [6] studies, much more in line to that with continuous infusion 5-FU alone. Table  5 shows grades 3/4 toxicities with irinotecan-based adjuvant treatment studies. Interestingly FOLFIRI showed very similar incidences of grades 3 or 4 diarrhoea, stomatitis and nausea/ vomiting to FOLFOX in adjuvant setting. However, neutropenia was much less common with FOLFIRI than FOLFOX. American Society of Clinical Oncology (ASCO) guidelines currently recommend that routine use of adjuvant chemotherapy is not indicated for medically fit stage II colon cancer patients [46] . However, ASCO guidelines suggested that several subsets of patients could be considered for adjuvant therapy. These include patients with poorly differentiated histology, T4 lesions, bowel perforation presentation and inadequately sampled lymph nodes (n < 13) [46, 47] . In an analysis of 35 787 cases of T3N0 colon cancer from the USA National Cancer Database, patients were stratified by the number of lymph nodes undergoing pathological examination [47] . The 5-year survival rates for 1-7 nodes examined was 49.8%, 8-12 nodes 56.2% and ‡13 lymph nodes 63.4% (P < 0.0001). The average yield of positive nodes did not significantly increase once 13 nodes were examined and this might represent the number of examined nodes necessary to adequately stage T3N0 tumour. A meta-analysis performed by a Canadian group based on 4187 patients found no significant survival benefit for adjuvant chemotherapy (risk ratio [RR]: 0.87; 95% CI: 0.75-1.01; P = 0.07) [48] . ASCO selected 12 trials based on the more stringent criteria requiring inclusion of a surgery-alone control arm and at least one 5-FU based chemotherapy arm. A meta-analysis based on these 12 trials again found no significant survival advantage (RR: 0.86; 95% CI: 0.73-1.02) [46] . However, the largest randomised trial addressing this issue was recently reported. In the QUASAR uncertain study [49] , 3239 patients were randomised between observation (n = 1617) or 5-FU/LV (n = 1622). 92% of patients in this study had stage II colon cancer. With a median follow-up of 4.6 years, adjuvant chemotherapy was associated with significantly reduced recurrence (RR: 0.78; 95% CI: 0.67-0.91; P = 0.001) and improved survival (RR: 0.83; 95% CI: 0.71-0.97; P = 0.02). The 5-year recurrence rates were 22.2% for chemotherapy arm and 26.2% for observation arm. The 5-year overall survival rates were 80.3% for chemotherapy arm and 77.4% for observation arm. Among the patients with stage II colon cancer, the survival benefit for chemotherapy was also significant (P = 0.04). In the MOSAIC study, FOLFOX was also associated with a nonsignificant improvement in DFS compared to LV5FU2, but the study was not powered to detect differences between treatment arms by disease stage.
However, one should emphasise that there is no universal consensus on the definition of high risk stage II colon cancer, but the ASCO guidelines could serve as a reasonable guide [46] . Additional molecular markers such as microsatellite instability (MSI) what is the optimal duration of chemotherapy?
Although the results from the Intergroup-0035 study led to the adoption of 5-FU and levamisole given for 12 months as standard adjuvant therapy, 30% of patients discontinued treatment prematurely because of toxicity with a median of 5-months' treatment [50] . Further US Intergroup studies (INT0089 and INT 0089-46-51) established 6 months as the standard duration of 5-FU/LV [22, 51] . In the GERCOR study comparing LV5FU2 with bolus 5-FU/LV, a second randomisation was performed between 24 and 36 weeks of treatment, no DFS or OS differences were seen [30, 31] . In the SAFFA study, 12 weeks of PVI 5-FU resulted in equivalent efficacy compared to 6 months of bolus 5-FU/LV [32] . Table 6 shows selected randomised studies where the duration of chemotherapy was addressed [22, 31, 32, 51] . These data were relevant as patients' quality of life would improve earlier if the duration of chemotherapy was shorter since 5-FU did not have long term side effects [43] . Moreover, as oxaliplatin induced neurotoxocity is related to its cumulative dose, shorter duration of treatment would translate into less disabling neurotoxicity for patients.
when should one start adjuvant chemotherapy after surgery?
Most clinical trials stipulated that adjuvant treatment to be started within 6-7 weeks of surgery. However, in real life situations there are often delays in commencing treatment. It is unclear whether delay in starting adjuvant chemotherapy would be detrimental to patients' survival. In a Swedish adjuvant therapy study in stage III colon cancer, patients who started treatment more than 8 weeks after surgery had worse survival compared to those who started within 8 weeks, and indeed survival was the same to those on observation alone [52] . Similarly, in the SAFFA study, significantly inferior survival was found for patients starting adjuvant therapy beyond 8 weeks after surgery [32] .
future directions in adjuvant therapy
With the advent of monoclonal antibodies in metastatic CRC, the next wave of adjuvant therapy trials is focusing on the use of these new targeted agents. Antibodies targeting against epidermal growth factor receptor such as cetuximab [53] and vascular endothelial growth factor such as bevacizumab [54] have both shown efficacy in the metastatic setting. Large scale phase III trials are now underway recruiting 14 000 patients. Table 7 shows on-going studies evaluating cetuximab and bevacizumab in the adjuvant setting. As these monoclonal antibodies have relatively mild side-effect profile compared to cytotoxic drugs, aside from assessing the additional benefit of these monoclonal antibodies over cytotoxic agents, the long term effects of these agents on cancer survivors and the optimal duration of these agents would be very important issues to address, bearing in mind the costs associated with these treatments.
Another important issue to address is the choice of first line regimen for recurrent or metastatic disease after FOLFOX adjuvant therapy. In breast cancer, once a patient has relapsed from an anthracycline-based adjuvant chemotherapy, a noncross resistant taxane-based regimen is usually preferred. Patients are seldom rechallenged with another anthracyclinebased chemotherapy as first line treatment for recurrent breast cancer. However, in advanced CRC, patients are only considered to be truly 5-FU refractory if they progress on or within 3 months of fluoropyrimidines-based treatment. Fluorouracil rechallenge ‡6 months after initial treatment is a reasonable treatment approach [55] , considering that first line combination treatment is not always necessary in advanced CRC [40, 56] . Therefore if patients do not have any residual neuropathy and there has been >6 months of disease free interval after adjuvant FOLFOX therapy, the choice between oxaliplatin and irinotecan-based chemotherapy should be individually tailored taking into account previous oxaliplatin-related toxicity. However, oxaliplatin-based therapy may be preferable if liver or pulmonary metastectomy is a primary treatment aim. Ultimately, only prospective RCTs can provide the answers, but focus should be on the partnership between cytotoxic and targeted therapy in this scenario rather than choosing between oxaliplatin or irinotecan-based therapy.
conclusions
Disease free survival has been increasingly used as a surrogate efficacy endpoint and its definition will require international agreement to interpret results from RCTs appropriately. Equivalent efficacy has been shown between continuous infusion 5-FU and bolus 5-FU. Oxaliplatin-based adjuvant chemotherapy is becoming the standard of care as adjuvant chemotherapy (at least in stage III colon cancer), whereas irinotecan should not be routinely used in adjuvant setting. Oral fluoropyrimidines had demonstrated equivalent efficacy to bolus 5-FU/LV as adjuvant treatment-its combination with oxaliplatin and monoclonal antibodies is currently being evaluated in randomised phase III studies. In terms of safety, a continuous infusion schedule has a more favourable safety profile than bolus schedule and capecitabine is similar to continuous infusion 5-FU/LV. Both continuous infusion 5-FU/ LV and capecitabine represent more optimal partners to oxaliplatin and irinotecan. However, the addition of oxaliplatin and irinotecan to fluoropyrimidines increases the toxicity and, in the case of IFL, compromised the efficacy due to excessive treatment-related deaths. For stage II colon cancer, adjuvant therapy remains an area of controversy. In medically fit patients, chemotherapy with 5-FU/LV can be offered, especially in those with high-risk characteristics such as intestinal perforation, T4 tumours, poorly differentiated tumours, inadequately pathologically examined (<13) lymph node and extramural venous or lymphatic invasion. For average risk patients, a discussion of the small benefit of chemotherapy should be made and the patient should be involved in the decision-making process. Oxaliplatin-based combination chemotherapy may be over-treatment in stage II colon cancer, as neurotoxicity can be prolonged and disabling. Six months of adjuvant treatment is the current standard duration and treatment should start within 8 weeks post surgery. However, 3 months of treatment may be enough and should be explored further.
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